TRIM21 and ovarian carcinoma: Another study, by Chatterjee et al. [32], suggested a role for AAbs in the surveillance of ovarian cancer and in predicting its recurrence, as AAbs to 5H6, HARS, CDR2 and Ro52 antigens predicted ovarian cancer recurrence 5.03 months before clinical onset in 21 patients, with a sensitivity of 90.5%.